Viking Therapeutics Showcases Metabolic Innovations at Upcoming Investor Conferences
- Viking Therapeutics is preparing for major investor conferences to enhance visibility and engage potential investors in 2026.
- The company’s VK2735 candidate is in Phase 3 trials for obesity, showing promising early safety and clinical results.
- VK2809, aimed at lipid and metabolic disorders, has met key endpoints in Phase 2 studies, indicating strong treatment potential.
Viking Therapeutics Advances Metabolic Therapies Amid Upcoming Conferences
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical firm focused on innovative treatments for metabolic and endocrine disorders, is preparing for a notable presence at several key investor conferences. With participation scheduled at the Leerink Partners Global Healthcare Conference and the Jefferies Biotech on the Beach Summit from March 8-11, 2026, the company aims to enhance visibility and engagement with potential investors. A critical aspect of this participation will be a fireside chat scheduled for March 10, 2026, where Viking's leadership will discuss the company's ongoing research and development efforts. This provides an opportunity to showcase their pipeline, with a live webcast and replay options to enhance accessibility for interested stakeholders.
Central to Viking's strategy are two innovative therapeutic candidates that are currently progressing through various stages of clinical trials. VK2735, a dual agonist targeting GLP-1 and GIP receptors, is undergoing a Phase 3 obesity program with two pivotal trials, VANQUISH-1 and VANQUISH-2. Early results from previous studies suggest that VK2735 holds substantial promise, demonstrating favorable safety and clinical benefits that could significantly impact obesity treatment landscapes. In addition to its ongoing trials, Viking is also advancing an oral formulation of VK2735, which could expand its therapeutic reach and facilitate patient adherence.
Furthermore, Viking is actively developing VK2809, an oral small molecule designed for lipid and metabolic disorders. This candidate has achieved notable milestones, such as meeting key endpoints in a Phase 2b study for nonalcoholic steatohepatitis (NASH) and associated fibrosis. Initial findings from a Phase 2a trial for nonalcoholic fatty liver disease (NAFLD) reveal that VK2809 significantly reduces LDL-C and liver fat compared to placebo, underpinning its potential as a treatment for prevalent metabolic conditions. Viking also explores novel dual amylin and calcitonin receptor agonists (DACRAs) targeting obesity, further emphasizing its commitment to advancing therapeutic options that enhance patient outcomes in metabolic health.
In related initiatives, Viking Therapeutics continues to prioritize partnerships and strategic collaborations to bolster its research and commercial capabilities. As the company showcases its advancements and future potential at the upcoming conferences, it stands at a critical juncture in the biopharmaceutical industry, poised to make a significant impact in the field of metabolic therapies.
